Submitted:
14 August 2023
Posted:
15 August 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- el Manouni el Hassani, S., et al., Risk Factors for Late-Onset Sepsis in Preterm Infants: A Multicenter Case-Control Study. Neonatology, 2019. 116(1): p. 42-51.
- Wynn, J.L., Defining neonatal sepsis. Curr Opin Pediatr, 2016. 28(2): p. 135-40.
- Dong, Y. and C.P. Speer, Late-onset neonatal sepsis:Recent developments. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2015. 100(3): p. F257-F263.
- Cantey, J.B. and J.H. Lee, Biomarkers for the Diagnosis of Neonatal Sepsis. 2021, W.B. Saunders. p. 215-227.
- Worku, M., et al., Role of complete blood cell count parameters in the diagnosis of neonatal sepsis. BMC Pediatrics, 2022. 22(1): p. 1-9.
- Sharma, D., et al., Biomarkers for diagnosis of neonatal sepsis : a literature review. 2017. 7058(November).
- Hornik, C.P., et al., Use of the complete blood cell count in late-onset neonatal sepsis. Pediatric Infectious Disease Journal, 2012. 31(8): p. 803-807.
- Shah, B.A. and J.F. Padbury, Neonatal sepsis an old problem with new insights. Virulence, 2014. 5(1): p. 163-171.
- Gude, S.S., et al., Biomarkers of neonatal sepsis: From being mere numbers to becoming guiding diagnostics. Cureus, 2022. 14(3).
- Eschborn, S. and J.-H. Weitkamp, Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. Journal of Perinatology, 2019. 39(7): p. 893-903.
- Atanasova V, R.R.H.A., Procalcitonin: an innovative marker for bacterial infections. Biochemical, immunological and clinical aspects (chapter 1)tle. Clinical application of immunological investigations" (International immunological journal for clinicians. 3(1):153-1.
- Ng, P.C. and H.S. Lam, Biomarkers for Late-Onset Neonatal Sepsis: Cytokines and Beyond. Clinics in Perinatology, 2010. 37(3): p. 599-610.
- Mitchell, E., Serum calcitonin gene-related peptide concentrations in the horse and their relationship to the Systemic Inflammatory response. 2006, Virginia Tech.
- Raúl Bustos, B. and C. Heriberto Araneda, Procalcitonina para el diagnóstico de la sepsis tardía en recién nacidos de muy bajo peso de nacimiento. Revista Chilena de Infectologia, 2012. 29(5): p. 511-516.
- Georgieva R, H.E., Dyankova D Diagnostic value of semi-quantitive testing of serum procalcitonin in newborns with generalized bacterial infections. . Pediatrics, 2001(4): p. 28-31.
- Eichberger, J. and B. Resch, Reliability of interleukin-6 alone and in combination for diagnosis of early onset neonatal sepsis: systematic review. Frontiers in Pediatrics, 2022. 10: p. 840778.
- Boskabadi, H. and M. Zakerihamidi, Evaluate the diagnosis of neonatal sepsis by measuring interleukins: A systematic review. Pediatrics and Neonatology, 2018. 59(4): p. 329-338.
- Boskabadi, H., et al., Serum interleukin 8 level as a diagnostic marker in late neonatal sepsis. Iranian Journal of Pediatrics, 2010. 20(1): p. 41-47.
- Bechard, D., et al., Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. Journal of Vascular Research, 2000. 37(5): p. 417-425.
- Kali, A. and K.S. Rathan Shetty, Endocan: A novel circulating proteoglycan. Indian Journal of Pharmacology, 2014. 46(6): p. 579-583.
- Buyuktiryaki, M., et al., Can Endocan Predict Late-Onset Neonatal Sepsis? Journal of Pediatric Infectious Diseases, 2019. 14(3): p. 96-102.
- Kuzniewicz, M.W., et al., Development and implementation of an early-onset sepsis calculator to guide antibiotic management in late preterm and term neonates. Joint Commission Journal on Quality and Patient Safety, 2016. 42(5): p. 232-239.
- Sofouli, G.A., et al., Early Diagnosis of Late-Onset Neonatal Sepsis Using a Sepsis Prediction Score. Microorganisms, 2023. 11(2).


| Clinical signs (new-onset): | Laboratory signs: | Risk factors: |
|---|---|---|
| Rhythmic breathing disorders (apnea, dyspea) | Low/high WBC count | Mechanical ventilation |
| Increased oxygen needs | Thrombocytopenia | Central venous line |
| Requirement of respiratory support | Positive prophylactic microbiological testing | Parenteral nutrition |
| Skin color changes (pale/greyish skin) | Hyper / hypoglycemia | Urinary catheter |
| Tachy/bradycardia | Methabolic acidosis | Gastral tube |
| Abdominal dystension | Postnatal corticosteroids | |
| Vomiting | Chronic respiratory and heart failure | |
| Diarrhea | ||
| Decreased motor activity | ||
| Depressed consciousness | ||
| Irritabilty, seizures | ||
| Bulged fontanelle | ||
| Jaundice | ||
| Weight loss | ||
| Hypothermia/ hyperthermia |
| Parameter | Group | N | SD | P | ||||
|---|---|---|---|---|---|---|---|---|
| 0 - 1 | 0 - 2 | 1 - 2 | ||||||
| PCT | 0. Controls | 17 | 0.43a | 0.57 | 0.004 | 0.858 | 0.005 | |
| 1. Symptomatic infected | 21 | 2.27b | 3.22 | |||||
| 2. Symptomatic uninfected | 18 | 0.44a | 0.58 | |||||
| ESM-1 | 0. Controls | 19 | 118.21a | 84.00 | 0.130 | 0.967 | 0.092 | |
| 1. Symptomatic infected | 21 | 163.52a | 125.11 | |||||
| 2. Symptomatic uninfected | 20 | 116.00a | 85.33 | |||||
| IL-6 | 0. Controls | 17 | 29.81a | 104.02 | 0.015 | 0.940 | 0.005 | |
| 1. Symptomatic infected | 18 | 30.72b | 53.48 | |||||
| 2. Symptomatic uninfected | 20 | 5.07a | 5.39 | |||||
| IL-8 | 0. Controls | 13 | 45.25a | 106.80 | 1.000 | 0.894 | 0.705 | |
| 1. Symptomatic infected | 14 | 141.98a | 346.59 | |||||
| 2. Symptomatic uninfected | 12 | 27.62a | 40.20 | |||||
| CRP | 0. Controls | 18 | 3.96a | 2.78 | 0.055 | 0.186 | 0.183 | |
| 1. Symptomatic infected | 20 | 21.24a | 30.13 | |||||
| 2. Symptomatic uninfected | 20 | 4.83a | 2.52 | |||||
| I:T index | 0. Controls | 17 | 0.29ac | 0.21 | 0.117 | 0.732 | 0.024 | |
| 1. Symptomatic infected | 20 | 0.35bc | 0.16 | |||||
| 2. Symptomatic uninfected | 18 | 0.24a | 0.11 | |||||
| Platelets PLT (х 109/L) | 0. Controls | 19 | 384.00a | 136.13 | 0.013 | 0.147 | 0.095 | |
| 1. Symptomatic infected | 21 | 265.57bc | 167.86 | |||||
| 2. Symptomatic uninfected | 20 | 321.90ac | 126.00 | |||||
| White blood cells WBC (х 109/L) | 0. Controls | 19 | 12.59a | 4.01 | 0.708 | 0.667 | 0.855 | |
| 1. Symptomatic infected | 21 | 16.87a | 13.34 | |||||
| 2. Symptomatic uninfected | 20 | 13.20a | 4.54 | |||||
| Parameter | Frequency | 0. Controls | 1. Symptomatic infected | 2. Symptomatic uninfected | P | ||
|---|---|---|---|---|---|---|---|
| 0 - 1 | 0 - 2 | 1 - 2 | |||||
|
PLT <150 (x 109/L) |
n | 0 | 7 | 1 | 0.006 | 0.330 | 0.022 |
| % | 0a | 33.3b | 5.0a | ||||
| WBC <5 and >21 (х 109/l) |
n | 1 | 10 | 2 | 0.003 | 0.587 | 0.009 |
| Parameter | Threshold value | Sensitivity (%) | Specificity (%) | Positive predictive value (%) | Negative predictive value(%) | Accuracy (%) | |
|---|---|---|---|---|---|---|---|
| PCT | ≥0.46* | 76 | 74 | 64 | 84 | 75 | |
| PCT | ≥0.5 | 71 | 74 | 63 | 81 | 73 | |
| IL-6 | ≥27.5* | 78 | 70 | 56 | 87 | 73 | |
| I:T index | ≥0.335* | 50 | 80 | 59 | 74 | 69 | |
| I:T index | ≥0.25 | 20 | 97 | 80 | 68 | 69 | |
| PLT | ≤161.5 | 43 | 97 | 90 | 76 | 78 | |
| PCT + IL-6 + I:T index + PLT | ≥ 0.276* | 94 | 68 | 63 | 95 | 78 | |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).